HK1080459A1 - Novel pyrimidineamide derivatives and the use thereof - Google Patents

Novel pyrimidineamide derivatives and the use thereof

Info

Publication number
HK1080459A1
HK1080459A1 HK05111972A HK05111972A HK1080459A1 HK 1080459 A1 HK1080459 A1 HK 1080459A1 HK 05111972 A HK05111972 A HK 05111972A HK 05111972 A HK05111972 A HK 05111972A HK 1080459 A1 HK1080459 A1 HK 1080459A1
Authority
HK
Hong Kong
Prior art keywords
derivatives
novel
pyrimidineamide
disease
benzoylaminophenyl
Prior art date
Application number
HK05111972A
Other languages
English (en)
Inventor
Paul William Manley
Werner Breitenstein
Sandra Jacob
Pascal Furet
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1080459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1080459A1 publication Critical patent/HK1080459A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
HK05111972A 2002-09-27 2005-12-23 Novel pyrimidineamide derivatives and the use thereof HK1080459A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222514.2A GB0222514D0 (en) 2002-09-27 2002-09-27 Organic compounds
PCT/EP2003/010724 WO2004029038A1 (en) 2002-09-27 2003-09-26 Novel pyrimidineamide derivatives and the use thereof

Publications (1)

Publication Number Publication Date
HK1080459A1 true HK1080459A1 (en) 2006-04-28

Family

ID=9944917

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111972A HK1080459A1 (en) 2002-09-27 2005-12-23 Novel pyrimidineamide derivatives and the use thereof

Country Status (24)

Country Link
US (1) US7655669B2 (xx)
EP (1) EP1546127B1 (xx)
JP (2) JP4463685B2 (xx)
KR (2) KR100876055B1 (xx)
CN (1) CN100404528C (xx)
AT (1) ATE369355T1 (xx)
AU (1) AU2003270277B2 (xx)
BR (1) BR0314797A (xx)
CA (1) CA2499822C (xx)
DE (1) DE60315479T2 (xx)
DK (1) DK1546127T3 (xx)
EC (1) ECSP055701A (xx)
ES (1) ES2288615T3 (xx)
GB (1) GB0222514D0 (xx)
HK (1) HK1080459A1 (xx)
MX (1) MXPA05003253A (xx)
NO (1) NO20051966L (xx)
NZ (1) NZ538930A (xx)
PL (1) PL374443A1 (xx)
PT (1) PT1546127E (xx)
RU (1) RU2378267C2 (xx)
SI (1) SI1546127T1 (xx)
WO (1) WO2004029038A1 (xx)
ZA (1) ZA200502304B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
DE10352979A1 (de) 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
CA2577275A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
AU2005281299B2 (en) 2004-09-09 2012-03-15 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
JP5373288B2 (ja) * 2005-01-28 2013-12-18 ノバルティス アーゲー Ｔｉｅ−２キナーゼ活性の調節に応答する疾患を処置するためのピリミジルアミノベンズアミドの使用
MY146795A (en) * 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
NZ575113A (en) 2006-09-22 2012-03-30 Novartis Ag Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
AU2007317349B2 (en) * 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
CN101720322A (zh) 2007-05-04 2010-06-02 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的化合物和组合物
CN101687853A (zh) * 2007-05-04 2010-03-31 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的嘧啶衍生物和组合物
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
KR101218926B1 (ko) 2007-08-22 2013-01-04 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
BRPI0815572A2 (pt) 2007-08-22 2015-02-18 Irm Llc Compostos e composições como inibidores de quinases
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
JP2013526513A (ja) * 2010-05-11 2013-06-24 クリサニ バイオサイエンシーズ プライベート リミッテッド ４，６−ジベンジルアミン−２−メチル−ピリミジン誘導体、および癌治療のためのそれらの使用
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
US5215989A (en) * 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
TW225528B (xx) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0025820D0 (en) 2000-10-20 2000-12-06 Novartis Ag Organic compounds
DE60212836T2 (de) 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
WO2005064409A2 (en) 2003-12-23 2005-07-14 Koninklijke Philips Electronics N.V. Removable pellicle for immersion lithography

Also Published As

Publication number Publication date
EP1546127B1 (en) 2007-08-08
KR20070098940A (ko) 2007-10-05
CA2499822A1 (en) 2004-04-08
EP1546127A1 (en) 2005-06-29
AU2003270277B2 (en) 2007-08-23
CA2499822C (en) 2012-04-10
JP4463685B2 (ja) 2010-05-19
BR0314797A (pt) 2005-07-26
US7655669B2 (en) 2010-02-02
MXPA05003253A (es) 2005-06-08
RU2378267C2 (ru) 2010-01-10
PL374443A1 (en) 2005-10-17
PT1546127E (pt) 2007-11-07
AU2003270277A1 (en) 2004-04-19
ES2288615T3 (es) 2008-01-16
GB0222514D0 (en) 2002-11-06
CN100404528C (zh) 2008-07-23
SI1546127T1 (sl) 2008-08-31
DE60315479T2 (de) 2008-04-30
US20060142577A1 (en) 2006-06-29
JP5178681B2 (ja) 2013-04-10
DK1546127T3 (da) 2007-12-10
KR20050047128A (ko) 2005-05-19
ZA200502304B (en) 2006-04-26
RU2005113153A (ru) 2006-11-10
JP2006508064A (ja) 2006-03-09
DE60315479D1 (de) 2007-09-20
WO2004029038A1 (en) 2004-04-08
NO20051966L (no) 2005-04-22
ATE369355T1 (de) 2007-08-15
KR100876055B1 (ko) 2008-12-26
NZ538930A (en) 2008-04-30
ECSP055701A (es) 2005-05-30
CN1684951A (zh) 2005-10-19
JP2010043113A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004005281A8 (en) Inhibitors of tyrosine kinases
TW200615266A (en) Organic compounds
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
IL153182A0 (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
MXPA05011671A (es) Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos.
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
TW200633701A (en) Thioether derivatives, their manufacture and use as pharmaceutical agents
TW200626591A (en) Amide derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110926